| Literature DB >> 27708827 |
Katia Noyes1, Janet Baack-Kukreja2, Edward M Messing2, Luke Schoeniger3, Eva Galka3, Wei Pan4, Cai Xueya5, Fergal J Fleming1, John Rt Monson1, Supriya G Mohile6, Todd Francone7.
Abstract
AIMS: To explore the feasibility of recruiting surgical oncology patients and implementing a surgical integrated discharge (SID) programme led by advanced practice providers (APP).Entities:
Keywords: Discharge process; integrated care; multidisciplinary care; readmission; surgical outcomes
Year: 2016 PMID: 27708827 PMCID: PMC5047346 DOI: 10.1002/nop2.52
Source DB: PubMed Journal: Nurs Open ISSN: 2054-1058
Figure 1Inpatient surgical care pathway. Advance scheduling of most surgical admissions provides an opportunity to plan for post‐discharge care (including availability of informal caregivers), time for comprehensive risk assessment, and patient self‐management training during pre‐operative and inpatient periods.
Figure 2Study Flowchart. The integrated care approach (A) started as soon as the decision about surgery was made and focused on streamlining care, avoiding delays, and minimizing patient burden. Usual surgical care pathways (B) are characterized by unnecessary appointments, redundant tests, and care inefficiencies.
Figure 3Summary of integrated care intervention. Each patient‐ and care‐related activity of this multidisciplinary intervention was incorporated into organization strategy and work flow diagrams for each care setting were modified appropriately.
Figure 4Study Enrollment. We recruited colorectal, bladder and pancreatic cancer patients age 50 and older who were considered for surgery between October 2013 and October 2014, and who were discharged home, with or without home care. Control group patients were selected using electronic medical records from surgical inpatients who underwent the same elective procedures a year prior to the intervention implementation (July 2012‐July 2013).
Patients characteristics
| Cases ( | Controls ( |
| |
|---|---|---|---|
| Race | |||
| Black | 2 (3·92) | 5 (4·42) | 0·910 |
| Other | 2 (3·92) | 7 (6·19) | |
| White | 47 (92·16) | 101 (89·38) | |
| Sex | |||
| Female | 21 (41·18) | 39 (34·51) | 0·412 |
| Male | 30 (58·82) | 74 (65·49) | |
| Cancer type | |||
| Colorectal | 22 (43·14) | 41 (36·28) | 0·664 |
| Pancreatic | 9 (17·65) | 25 (22·12) | |
| Urology | 20 (39·22) | 47 (41·59) | |
| Insurance | |||
| Medicare | 27 (52·94) | 51 (245·13) | 0·640 |
| Others | 2 (3·92) | 6 (5·31) | |
| Private | 22 (43·14) | 56 (49·56) | |
| Readmitted | |||
| Not Readmitted | 42 (84·31) | 94 (83·19) | 0·857 |
| Readmitted | 8 (15·69) | 19 (16·81) | |
| Age | 72·02 (8·39) | 66·88 (9·49) | 0·001 |
| Comorbidity score | 2·69 (2·09) | 2·66 (1·8) | 0·944 |
| ASA score | 2·84 (0·58) | 2.8 (0·6) | 0·642 |
| Time | 742·98 (198·91) | 478·42 (102·9) | <0·001 |
| Total costs | 26607 (17220) | 22827 (14669) | 0·150 |
| Length of stay | 8·78 (6·95) | 8·02 (5·81) | 0·463 |
ASA Score, American Society of Anesthesiologists’ perioperative risk score; LOS, length of stay.
Multivariate analysis of the impact of patient and tumour characteristics on inpatient length of stay, readmission rate and total 90‐day costs
| Variable | Total cost | Length of stay | Readmission |
|---|---|---|---|
| Coefficient | IRR | OR | |
| 0·01 | 1·01 | 1·01 | |
| Black vs. White | −0·13 | 1·05 | <0·001 |
| Other vs. White | 0·18 | 0·85 | 0·49 |
| Male vs. female | 0·01 | 1·00 | 1·30 |
| Pancreatic cancer | 0·24 | 1·25 | 2·86 |
| Bladder cancer | 0·08 | 0·75 | 2·92 |
| Blood Lost | 0·19 | 1·23 | |
| Case vs. Control | 0·37 | 0·42 | 0·94 |
| ASA Score | 1·08 | ||
| Comorbidity Score | 1·01 | ||
| Follow‐up, days | 1·00 |
P < 0·05.
ASA Score, American Society of Anesthesiologists’ perioperative risk score; IRR, incidence rate ratio from negative binomial model (IRR >1 means greater LOS compared with the reference group); OR, odds ratio from logistic analysis (OR >1 means greater readmission risk).
Univariate analyses of the study outcomes: length of stay, readmissions and total 90‐day total healthcare costs, by individual risk factors
| Name | Description | LOS, Mean days | Not readmitted | Readmitted | Total Cost Mean $ | ||
|---|---|---|---|---|---|---|---|
| Race | Black | 7·14 | 7 (5·11) | 0 (0) | 21,046 | ||
| Other | 7·11 | 8 (5·84) | 1 (3·7) | 21,618 | |||
| White | 8·38 | 122 (89·05) | 26 (96·3) | 24,287 | |||
| Sex | Female | 7·87 | 53 (38·69) | 7 (25·93) | 22,822 | ||
| Male | 8·48 | 84 (61·31) | 20 (74·07) | 24,683 | |||
| Cancer type | Colorectal | 7·68 | 58 (42·34) | 5 (18·52) | 21,085 | ||
| Pancreatic | 9·88 | 27 (19·71) | 7 (25·93) | 24,684 | |||
| Bladder | 7·97 | 52 (37·96) | 15 (55·56) | 26,399 | |||
| Insurance | Medicare | 9·14 | 64 (46·71) | 14 (17·95) | 26,968 | ||
| Others | 7·38 | 7 (5·11) | 1 (3·7) | 23,701 | |||
| Private | 7·46 | 66 (48·18) | 12 (15·38) | 21,067 | |||
| Intervention | Case | 8·78 | 43 (31·39) | 8 (29·63) | 26,607 | ||
| Control | 8·02 | 94 (68·61) | 19 (70·37) | 22,827 | |||
| Age | 68·34 | 9·41 | 69·15 | 9·74 | |||
| Comorbidity | 2·66 | 1·96 | 2·7 | 1·46 | |||
| ASA Score | 2·82 | 0·61 | 2·78 | 0·51 | |||
| Follow‐up, days | 550 | 183 | 580 | 170 | |||
The P values were calculated by anova for numerical covariates; and by chi‐square test or Fisher's exact for categorical covariates (*P < 0·05).
ASA score, American Society of Anesthesiologists’ perioperative risk score; LOS, length of stay.